Citable filing context
DD's research view summarizes recent SEC filing context, starting with legal_settlement from Sep 10, 2026.
| Filed | Item | Context |
|---|---|---|
| Sep 10, 2026 | legal_settlement | DuPont, Chemours, and Corteva agreed to a $455 million settlement regarding PFAS contamination in North Carolina. |
| Aug 4, 2026 | earnings | DuPont reported second quarter 2026 results with $1.8 billion in net sales and raised full-year 2026 guidance. |
| Jun 24, 2026 | other | DuPont de Nemours, Inc. implemented a 1-for-3 reverse stock split effective June 24, 2026. |
| Aug 4, 2026 | Guidance: adjusted_eps | 3.65 to 3.80 |
| Aug 4, 2026 | Guidance: adjusted_eps | 7.17 to 7.32 |
| Aug 4, 2026 | Guidance: operating_ebitda | 890.00 to 910.00 |
| Aug 4, 2026 | mda_quarterly | DuPont reported net sales of $1.8 billion for the second quarter of 2026, a 4% increase driven by organic growth in both the Healthcare & Water Technologies and Diversified Industrials segments. Healthcare & Water Technologies benefited from volume growth in personal protection, biopharma, and industrial water markets, while Diversified Industrials saw strength in aerospace, electric vehicle applications, and construction. The company’s financial profile has been significantly reshaped by the April 2026 divestiture of its Aramids business for $1.2 billion in cash and the November 2025 separation of its Electronics Business into Qnity. These transactions, alongside a 1-for-3 reverse stock split effective June 2026, reflect a strategic focus on core advanced solutions. Liquidity remains robust, with $1.7 billion in cash and cash equivalents as of June 30, 2026. Operating cash flow improved to $632 million for the first half of 2026, up from $151 million in the prior year, bolstered by higher earnings and working capital improvements. DuPont continues to execute a $2 billion share buyback authorization and maintains a commitment to investment-grade credit ratings. Management is currently implementing the 2026 DuPont Restructuring Program, targeting $100 million to $150 million in cost savings through 2028. |
| May 5, 2026 | mda_quarterly | DuPont reported first-quarter 2026 net sales of $1.7 billion, a 4% increase driven by 2% organic growth and favorable currency impacts. Healthcare & Water Technologies sales rose 6%, fueled by medical packaging and biopharma volume, though Middle East logistics disruptions hampered water technologies. Diversified Industrials saw flat organic growth, as strength in aerospace and automotive markets was offset by weakness in construction, printing, and packaging. The company is executing a major portfolio transformation, completing the separation of its Electronics business into Qnity Electronics and the $1.2 billion divestiture of its Aramids business. Liquidity is supported by $0.7 billion in cash and $2.0 billion in working capital, with new credit facilities totaling $2.75 billion expected in May 2026. Key headwinds include geopolitical uncertainty in the Middle East and a long-term settlement with New Jersey regarding PFAS and other substances. To streamline operations, DuPont initiated a restructuring program with anticipated charges of $100 million to $150 million through 2028. Capital allocation remains focused on shareholder returns, including a $0.20 quarterly dividend and a $2 billion share buyback authorization, with a $275 million accelerated repurchase planned for May 2026. |
Source: SEC EDGAR filing text and events; period Sep 10, 2026; filed Sep 10, 2026.
DD company research is free during early access. All you need is an account, with no card required. The five showcase tickers (TSLA, NVDA, AAPL, AMZN, PLTR) and the macro dashboard stay open without one.
Continue research
Follow same-sector companies and source explainers connected to the research view.
A factual guide to SEC Form 8-K current reports and the material company events they can disclose between quarterly filings.
A factual guide to quarterly SEC Form 10-Q reports, how they differ from annual 10-K filings, and what readers can inspect first.
A factual guide to Form S-1 registration statements and the disclosures companies provide before a public offering.
A factual guide to the core 10-K sections investors use for company context: business description, risk factors, MD&A, financial statements, and segment disclosures.